NasdaqGS:NVAXBiotechs
Novavax (NVAX) Valuation Check as FDA Scrutiny Rises and Activist Pushes for Possible Sale
Novavax (NVAX) is back in the spotlight after a controversial FDA memo signaled tougher vaccine approval standards, just as an activist shareholder ramps up pressure for a potential sale of the company.
See our latest analysis for Novavax.
Those cross-currents help explain why, at a share price of $6.57, Novavax has a weak short term share price return and a deeply negative multi year total shareholder return. This suggests momentum is still fading despite flashes of optimism around...